Radiation boosts immunotherapy in resistant head and neck cancers
NCT ID NCT03085719
First seen Jun 17, 2026 · Last updated Jun 17, 2026
Summary
This study tests whether adding focused radiation to the immunotherapy drug pembrolizumab (Keytruda) can help people with advanced head and neck cancer whose disease has worsened despite prior treatment. About 18 participants will receive different radiation doses alongside the immunotherapy. The main goal is to see if this combination can stop cancer growth for at least 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.